Function of Cardiac Myocytes in Ischemicheart Disease: Comparative Changes in Right and Left Ventricular Cells

  • Sian E. Harding
  • Federica del Monte
  • Philip A. Poole-Wilson
Part of the Progress in Experimental Cardiology book series (PREC, volume 1)


The contraction and relaxation velocities of single myocytes isolated from failing and nonfailing left and right human ventricles have been compared in order to investigate the possible contribution of cellular changes to the diastolic dysfunction seen in vivo. Myocytes from the failing right ventricle (RV) showed slowed relaxation compared to those from nonfailing, and the change was quantitatively similar to that seen in the failing left ventricle (LV). Poor relaxation was observed in RV myocytes from patients with ischemic heart disease, idiopathic dilated cardiomyopathy, and congenital heart disease. Division of patients into groups with high and low pulmonary artery pressure (PAP) showed a significant relation between raised PAP and slow relaxation of RV myocytes. Cells from the high PAP group were also longer, but not wider, than those from the low PAP group. β-adrenoceptor desensitization was evident in RV myocytes from failing heart, but did not diger in magnitude between high and low PAP groups. As we have previously shown for the LV, diastolic dysfunction in the RV may be related to changes in myocyte function.


Right Ventricular Pulmonary Artery Pressure Sarcomere Length Primary Pulmonary Hypertension Contraction Amplitude 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    del Monte F, O’Gara P, Poole-Wilson PA, Yacoub MH, Harding SE. 1995. Cell geometry and contractile abnormalities of myocytes from failing human left ventricle. Cardiovasc Res 30:281–290.PubMedCrossRefGoogle Scholar
  2. 2.
    Harding SE, Jones SM, O’Gara P, del Monte F, Vescovo G, Poole-Wilson PA. 1992. Isolated ventricular myocytes from failing and non-failing human heart; the relation of age and clinical status of patients to isoproterenol response. J Mol Cell Cardiol 24:549–564.PubMedCrossRefGoogle Scholar
  3. 3.
    Davies CH, Davia K, Bennett JG, Pepper JR, Poole-Wilson PA, Harding SE. 1995. Reduced contraction and altered frequency response of isolated ventricular myocytes from patients with heart failure. Circulation 92:2540–2549.PubMedGoogle Scholar
  4. 4.
    Souffer R, Wohlgelernter D, Vita NA, Amuchestegui M, Sostman HD, Berger H, Zaret B. 1985. Intact systolic left ventricular function in clinical congestive heart failure. Am J Cardiol 55:1032–1036.CrossRefGoogle Scholar
  5. 5.
    Litwin SE, Grossman W. 1993. Diastolic dysfunction as a cause of heart failure (review). J Am Coll Cardiol 22:49A–55A.PubMedCrossRefGoogle Scholar
  6. 6.
    Fowler MB, Laser JA, Hopkins GL, Minobe W, Bristow MR. 1986. Assessment of the B-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response. Circulation 74:1290–1302.PubMedGoogle Scholar
  7. 7.
    Mulieri LA, Hasenfuss G, Leavitt BJ, Allen PD, Alpert NR. 1992. Altered myocardial force-frequency relation in human heart failure. Circulation 85:1743–1750.PubMedGoogle Scholar
  8. 8.
    Rihal CS, Nishimura RA, Hade LK, Bailey KR, Tajik J. 1994. Systolic and diastolic dysfunction in patients with clinical diagnosis of dilated cardiomyopathy. Circulation 90:2772–2779.PubMedGoogle Scholar
  9. 9.
    Gwathmey JK, Copelas L, MacKinnon R, Schoen FJ, Feldman MD, Grossman W, Morgan JP. 1987. Abnormal intracellular calcium handing in myocardium from patients with end stage heart failure. Cardiovasc Res 61:70–76.Google Scholar
  10. 10.
    Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R, Zera P, Menlove R, Shah P, Jamieson S, Stinson EB. 1986. B1-and B2-adrenergic receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective B1-receptor down-regulation in heart failure. Circ Res 59:297–309.PubMedGoogle Scholar
  11. 11.
    Gwathmey JK, Slawsky MT, Hajjar RJ, Briggs GM, Morgan JP. 1990. Role of intracellular calcium handling in force-interval relationships of human ventricular myocardium. J Clin Invest 85:1599–1613.PubMedGoogle Scholar
  12. 12.
    Schwinger RHG, Bohm M, Muller-Ehmsen J, Uhlman R, Schmidt U, Stablein A, Ubetfuhr P, Kreuzer E, Reichart B, Eissner H-J, Erdmann E. 1993. Effect of inotropic stimulation on the negative force-frequency relationship in the failing human heart. Circulation 88:2267–2276.PubMedGoogle Scholar
  13. 13.
    Gerdes AM, Kellerman SE, Moore JA, Muffly KE, Clark LC, Reaves PY, Malec KB, McKeown PP, Schocken DD. 1992. Structural remodeling of cardiac myocytes in patients with ischemic cardiomyopathy. Circulation 86:426–430.PubMedGoogle Scholar
  14. 14.
    Beltrami CA, Finato N, Rocco M, Feruglio GA, Puricelli C, Cigola E, Quaini F, Sonnenblick EH, Olivetti G, Anversa P. 1994. Structural basis of end-stage failure in ischemic cardiomyopathy in humans. Circulation 89:151–163.PubMedGoogle Scholar
  15. 15.
    Yu CM, Sanderson JE, Chan S, Yeung L, Hung YT, Woo KS. 1996. Right ventricular diastolic dysfunction in heart failure. Circulation 93:1509–1514.PubMedGoogle Scholar
  16. 16.
    Harding SE, Vescovo G, Kirby M, Jones SM, Gurden J, Poole-Wilson PA. 1988. Contractile responses of isolated rat and rabbit myocytes to isoproterenol and calcium. J Mol Cell Cardiol 20:635–647.PubMedCrossRefGoogle Scholar
  17. 17.
    Gerdes AM, Capasso JM. 1995. Structural remodelling and mechanical dysfunction of cardiac myocytes in hem failure. J Mol Cell Cardiol 27:849–856.PubMedCrossRefGoogle Scholar
  18. 18.
    Poole-Wilson PA. 1995. The dimensions of human cardiac myocytes; confusion caused by methodology and pathology (comment). J Mol Cell Cardiol 27:863–865.PubMedCrossRefGoogle Scholar
  19. 19.
    Danielsen W, van der Leyen H, Meyer W, Neumann J, Schmitz W, Scholz H, Starbatty J, Stein B, Doring V, Kalmar P. 1989. Basal and isoprenaline-stimulated cAMP content in failing versus nonfailing human cardiac preparations. J Cardiovasc Pharmacol 14:171–173.PubMedCrossRefGoogle Scholar
  20. 20.
    von der Leyen H, Mende U, Meyer W, Neumann J, Nose M, Schmitz W, Scholz H, Starbatty J, Stein B, Wenzlaff, Doring V, Kalmar P, Haverich A. 1991. Mechanism underlying the reduced positive inotropic effects of the phosphodiesterase III inhibitors pimobendan, adibendan and saterinone in failing as compared to nonfailing human cardiac muscle preparations. Naunyn-Schmiedebergs Arch Phamacol 344:90–100.Google Scholar
  21. 21.
    Bohm M, Reiger B, Schwinger RHG, Erdmann E. 1994. cAMP concentrations, cAMP dependent protein kinase activity, and phospholamban in non-failing and failing myocardium. Cardiovasc Res 28:1713–1719.PubMedCrossRefGoogle Scholar
  22. 22.
    Wynne DG, del Monte F, Harding SE. 1996. Cyclic AMP levels in ventricular myocytes from noradrenaline-treated guinea-pigs. Eur J Pharmacol 310:235–242.PubMedCrossRefGoogle Scholar
  23. 23.
    Harding SE, Brown LA, del Monte F, Davies CH, O’Gara P, Vescovo G, Wynne DG, Poole-Wilson PA. 1996. Acceleration of contraction by β-adrenoceptor stimulation is greater in ventricular myocytes from failing than non-failing human hearts. Basic Res Cardiol 91(Suppl 2):53–56.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1998

Authors and Affiliations

  • Sian E. Harding
    • 1
  • Federica del Monte
    • 1
  • Philip A. Poole-Wilson
    • 1
  1. 1.Imperial College School of Medicine at the National Heart & Lung InstituteUK

Personalised recommendations